195 related articles for article (PubMed ID: 25683755)
1. Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.
Liewer S; Huddleston AN
Expert Rev Anticancer Ther; 2015 Apr; 15(4):453-64. PubMed ID: 25683755
[TBL] [Abstract][Full Text] [Related]
2. [Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].
Bartal A; Mátrai Z; Szucs A; Belinszkaja G; Langmár Z; Rosta A
Orv Hetil; 2012 Jan; 153(2):66-78. PubMed ID: 22217686
[TBL] [Abstract][Full Text] [Related]
3. Adherence to oral cancer therapies: nursing interventions.
Winkeljohn D
Clin J Oncol Nurs; 2010 Aug; 14(4):461-6. PubMed ID: 20682501
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of antineoplastic agents: the challenges for healthcare professionals.
Tadic D; Spasojevic IB; Tomasevic ZI; Dejanovic SD
J BUON; 2015; 20(3):690-8. PubMed ID: 26214619
[TBL] [Abstract][Full Text] [Related]
5. A review on adherence management in patients on oral cancer therapies.
Wood L
Eur J Oncol Nurs; 2012 Sep; 16(4):432-8. PubMed ID: 22051845
[TBL] [Abstract][Full Text] [Related]
6. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents.
Bedell CH
Clin J Oncol Nurs; 2003; 7(6 Suppl):5-9. PubMed ID: 14705494
[TBL] [Abstract][Full Text] [Related]
7. Managing oral chemotherapy: the healthcare practitioner's role.
Viele CS
Am J Health Syst Pharm; 2007 May; 64(9 Suppl 5):S25-32. PubMed ID: 17468153
[TBL] [Abstract][Full Text] [Related]
8. An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study.
Spoelstra SL; Given BA; Given CW; Grant M; Sikorskii A; You M; Decker V
Cancer Nurs; 2013; 36(1):18-28. PubMed ID: 23235499
[TBL] [Abstract][Full Text] [Related]
9. [Patient's beliefs about oral targeted therapies and impact on drug adherence in lung cancer: A pilot prospective study].
Torrecillas S; Perrot E; Gérinière L; Locatelli-Sanchez M; Laffay L; Souquet PJ; Couraud S
Rev Pneumol Clin; 2016 Feb; 72(1):25-34. PubMed ID: 26210879
[TBL] [Abstract][Full Text] [Related]
10. Are patients on oral chemotherapy in your practice setting safe?
Moody M; Jackowski J
Clin J Oncol Nurs; 2010 Jun; 14(3):339-46. PubMed ID: 20529795
[TBL] [Abstract][Full Text] [Related]
11. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.
Gebbia V; Bellavia G; Ferraù F; Valerio MR
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S49-59. PubMed ID: 22149481
[TBL] [Abstract][Full Text] [Related]
12. Adherence and oral agents with older patients.
Maloney KW; Kagan SH
Semin Oncol Nurs; 2011 May; 27(2):154-60. PubMed ID: 21514484
[TBL] [Abstract][Full Text] [Related]
13. Feasibility pilot on medication adherence and knowledge in ambulatory patients with gastrointestinal cancer.
Sommers RM; Miller K; Berry DL
Oncol Nurs Forum; 2012 Jul; 39(4):E373-9. PubMed ID: 22750908
[TBL] [Abstract][Full Text] [Related]
14. Oral chemotherapy food and drug interactions: a comprehensive review of the literature.
Segal EM; Flood MR; Mancini RS; Whiteman RT; Friedt GA; Kramer AR; Hofstetter MA
J Oncol Pract; 2014 Jul; 10(4):e255-68. PubMed ID: 24756141
[TBL] [Abstract][Full Text] [Related]
15. Patient adherence with oral oncolytic therapies.
Vioral A; Leslie M; Best R; Somerville D
Semin Oncol Nurs; 2014 Aug; 30(3):190-9. PubMed ID: 25085031
[TBL] [Abstract][Full Text] [Related]
16. Overview of the challenges related to oral agents for cancer and their impact on adherence.
Tipton JM
Clin J Oncol Nurs; 2015 Jun; 19(3 Suppl):37-40. PubMed ID: 26030391
[TBL] [Abstract][Full Text] [Related]
17. Adherence to oral anticancer chemotherapies and estimation of the economic burden associated with unused medicines.
Matti N; Delon C; Rybarczyk-Vigouret MC; Khan GM; Beck M; Michel B
Int J Clin Pharm; 2020 Oct; 42(5):1311-1318. PubMed ID: 32857257
[TBL] [Abstract][Full Text] [Related]
18. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.
Ribed A; Escudero-Vilaplana V; Romero-Jimenez RM; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2016; 15(4):427-35. PubMed ID: 26854363
[TBL] [Abstract][Full Text] [Related]
19. NCCN Task Force Report: Oral chemotherapy.
Weingart SN; Brown E; Bach PB; Eng K; Johnson SA; Kuzel TM; Langbaum TS; Leedy RD; Muller RJ; Newcomer LN; O'Brien S; Reinke D; Rubino M; Saltz L; Walters RS
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 3():S1-14. PubMed ID: 18377852
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center.
Solomon JM; Ajewole VB; Schneider AM; Sharma M; Bernicker EH
J Oncol Pharm Pract; 2019 Oct; 25(7):1564-1569. PubMed ID: 30170514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
